Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -1.3% 76.00 75.50 78.00 78.00 71.00 78.00 416,167 16:46:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 93.8 346

Ekf Diagnostics Share Discussion Threads

Showing 2601 to 2621 of 3025 messages
Chat Pages: Latest  109  108  107  106  105  104  103  102  101  100  99  98  Older
DateSubjectAuthorDiscuss
18/11/2020
17:01
Wan,Just read your post 1019 and seems we are agreed
richman777114
18/11/2020
16:59
hello,i'm a long term EKF shareholderprobably repeating what's already been observed by Wan and others but surely a quantitative (rather than just qualitative) antibody test per EKF/Kantaro is just what the doctor ordered (sorry) when it comes to assessing post vaccination immunity?
richman777114
18/11/2020
15:28
Keep up the good work, wan. Fantastic research that you generously share with others here. Very much appreciated.
speedsgh
18/11/2020
14:14
Yes, it is a lower cost product, but antigen testing is already experiencing strong interest and strong growth in demand, but in my view, it's set for very significant rates of growth.
wan
18/11/2020
14:07
I have been monitoring Thermo Fisher and as previously highlighted, Thermo Fisher has been selling PrimeStore MTM - PrimeStore™ MTM Molecular Transport Media PrimeStore™ MTM is a FDA Cleared Microbial nucleic acid storage and stabilization device. It inactivates microbes (to include SARS-CoV-2), stabilizes RNA/DNA and is on the US FDA list of primary sample collection devices for SARA-CoV-2 molecular testing. $425.00 - $438.00 hTTps://www.fishersci.com/shop/products/molecular-transport-media-2/p-8986001 Although ATM was previously listed I could not get any details. So the following is an interesting development - Longhorn Vaccines And Diagnostics LLC PRIMESTORE ATM 1.5ML RUO 50/PK Manufacturer: Longhorn Vaccines And Diagnostics LLC LHNATM15 $225.00 / Pack of 50 This product has been made available for purchase due to recent demand, however information about the product is limited. Please contact customer service with any questions. hTTps://www.fishersci.com/shop/products/23100405/23100405?searchHijack=true&searchTerm=23100405&searchType=RAPID&matchedCatNo=23100405 So, the demand I was expecting, due to the dramatic increase in antigen testing, has materialized and 'started' to be felt. Subsequently, one assumes that ATM production is, or will be, ramped up accordingly.
wan
18/11/2020
08:13
It also highlights the merits of responsible investing....do good as well as (hopefully) achieving good returns.
wan
18/11/2020
07:56
Longhorn Vaccines have been nominated as a finalist in COVID-19 Impact Award. The following contains a typo though regarding the quantities of ATM distributed (should have read MTM) - Longhorn Vaccines Longhorn Vaccines and Diagnostics isn’t a name that many people may have known of before COVID-19, but they have become one of the most impactful regional companies tackling the pandemic. As early as February, the company was tapped by the FDA to increase the production of its specialized product to rectify sample collection shortages; a critical gap in the COVID-19 testing supply chain. As one of the only US suppliers, Longhorn quickly ramped up production capability to over 1 million per week in early Spring. To date, they have produced and distributed more than 30,000,000 sample collection tubes containing their innovative PrimeStore Analyte Transport Media (ATM)Ⓡ, which could revolutionize antigen and molecular testing by completely eliminating the need for RNA and DNA extraction which will speed up testing and allow for improved point of care diagnosis. When Coca-Cola was tapped to further address the supply chain gap of COVID-19 test collection tubes, Longhorn was brought in to validate the tubes and confirm that the soda bottle preforms are compatible with COVID-19 testing systems. As of July, Longhorn has been awarded $225.8M in government contracts for COVID-19-related work, all of which are being provided by the Department of Homeland Security (DHS), according to USA Today’s story. Without innovators like Longhorn, led by President, Jeff Fischer, who responded quickly to address these mass-testing challenges, the US would not have been able to achieve the testing capacity needed to meet such an unprecedented demand. There is no doubt that the team at Longhorn and their partners have saved thousands of lives. hTTps://biobuzz.io/announcing-finalists-for-1st-annual-biobuzz-awards/ I am not the only one to pick up on the potential for ATM to enhance and allow for improved point of care testing.
wan
18/11/2020
07:48
Edit- EKF's antibody partnership announcement link added
wan
18/11/2020
07:45
I highlight the following article as it demonstrates important differentiating features for antibody tests, as well as raising questions in the use of public money (including in the UK) and why certain government contracts here in the UK are starting to attract scrutiny and indeed legal action - BARDA Awards $820K to DiaSorin to Develop Enhanced SARS CoV-2 IgG Antibody Assay Nov 17, 2020 NEW YORK ─ The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) announced Tuesday that it has awarded $820,000 to DiaSorin to develop an immunoassay that detects antibodies to SARS-CoV-2 in the serum or plasma of a person recently infected with the coronavirus. By enabling semi-quantitative monitoring of immune status, the test would overcome limitations of DiaSorin's Liaison SARS-CoV-2 S1/S2 IgG assay. If a COVID-19 vaccine receives authorization or approval, the new test could provide critical information to essential workers, people with a compromised immune system, and others, BARDA said. Full story - hTTps://www.360dx.com/regulatory-news-fda-approvals/barda-awards-820k-diasorin-develop-enhanced-sars-cov-2-igg-antibody#.X7TLPmj7Q2w What this effectively highlights is the growing importance for antibody testing, but also highlights key differentiating features of Kantaro's/EKF antibody tests, tests that are available now, not in development! For starters, a key differentiating aspect is that the Kantaro/EKF antibody test is quantitative (not qualitative, or indeed semi-quantitative) and importantly the test has already been used in a highly diverse population of over 75,000 patient samples. Resulting in EKF offering a high precision test that has demonstrated 97.8% sensitivity and 99.6% specificity for detecting COVID-19 specific IgG antibodies - hTTps://www.ekfdiagnostics.com/ekf-and-kantaro-biosciences-partner-to-market-quantitative-covid-antibody-testing-in-uk-and-europe.html
wan
17/11/2020
23:52
Once gain grateful to Wan and others for posting so much useful information - without any ramping as far as I am concerned. I took Tongosti's recent advice and filtered him long ago. Which is a shame because a contrarian view is useful and he has some useful commentary - so I sometimes view posts. But his condescending and arrogant attitude to other posters are the reason he will remain filtered. A message is much more powerful if you remain humble while delivering it - otherwise you switch people off and that is what is happening here. Tongosti may profess to know how Mr Market works, but humility is not something he has learned yet.
melody9999
17/11/2020
19:07
Calling the market top both ways is indeed the specialty of an insecure individual. Love these boards and their quality.
tongosti
17/11/2020
19:05
Tongosti - filtered. Insecure posting to themselves. Otherwise a good board. Seems a lot of covid sell off for testing companies right now. A lot of vaccine noise that will die down as people get used to the timeframe. Test test test
kiwipunter
17/11/2020
19:03
That's the spirit chaps.
tongosti
17/11/2020
18:58
james... everybody seems to have him filtered so he's posting to no-one but himself.
petewy
17/11/2020
17:33
By all means do - I am never after similar views but rather contrasting one. But that's me. An open mind is like a parachute - it only works if it's open. Unfortunately that's not the base case on these boards. Most forget that Mr Market is the ultimate judge of the game not some bored grandad going online preaching consensus building (all because he may be long and does not like to read opposing views).
tongosti
17/11/2020
17:14
Thanks for the support CD. I won't respond to every post (nor get into any slanging matches), but it has helped to differentiate between the two schools of thought. It will thus be interesting to see what the next few months brings.
wan
17/11/2020
16:55
You're very welcome to keep your opinions to yourself pal. If you do not like my challenging consensus views - PLEASE filter me. Ta.
tongosti
17/11/2020
16:52
tongosti, Wan has produced loads of valuable, time-consuming research. I'm sure the majority here welcome and value his contribution and would not wish it to stop. Whilst I have some sympathy for your short term/trading philosophy, none of us wants to see this board descend into the juvenile name-calling playground that has destroyed many other boards (look at the original PLUS board if you want to see this in action.) I, for one, would like you to stop the constant reaction/rebuttal to every one of Wan's postings. You've made your point. May I suggest it's time to move on. Thank you, CD
cambridgedon
17/11/2020
16:31
Depends what you call "research" pal. As you have seen mine has produced +53% in only three trades. I leave the entertainment and storytelling (and a complete lack of understanding how Mr Market works) to you. If it makes you feel any better, I will "like" your incessant ramping. LOL
tongosti
17/11/2020
14:28
If you agree on the testing front, then that sits somewhat awkwardly with your view on the effect from vaccines. Has the market discounted in the potential from the low-cost ATM product? In this regard the jury is definitely out, in other words, it appears to have discounted in not much coming from ATM. So time will tell. (but Longhorns comments/confidence are firmly in my mind). Has the market discounted in the 'potential' IPO of Trellus Health (note EKF's track record)? I think not, but time will tell. Has the market discounted in the rebound in the core business? To a degree maybe. Has the market discounted in the growth from the imminent new life science products? I don't think so. EKF's growing cash and marketable investments might mean next years dividend will be increased. Likewise, investors will be supportive if they use some of that cash to support further partnerships with Mount Sinai, with a view to going down the IPO route and distribute further dividends in-specie. How would the market discount that unknown but real potential? What could Trellus Health be worth? What could the resulting dividend in-specie be worth, what would the cash dividend and the potential Trellus Health in-specie dividend combined be worth in terms of dividend yield? Has the market correctly discounted the potential from the new antibody tests, especially in relation to the vaccine news? Difficult to say, but it should be noted that understanding the level of immune response, or how the vaccine response may behave differently to the response from natural infection, and understanding the duration of protection will remain uncertain for a number of years (amongst others aspects), but will be of key interest. So an accurate, data rich, diverse clinical use quantitative antibody test should be in demand, and that demand and interest should last for a number of years, not months. Because up until now, the vaccines manufacturers don't know the answers yet, and nor does the market! In short, I am not sure EKF get the in-depth coverage for 'everything' to be discounted. But I could be wrong, so please conduct your own research.
wan
17/11/2020
12:13
I also agree on the testing front, like i have said before. Markets reaction post Pfizer news (+ hugely overextended price) should alert people that it is a high probability that the market has discounted all you think. As for dividends, what good are they if the share price goes meaningfully down from here?
tongosti
Chat Pages: Latest  109  108  107  106  105  104  103  102  101  100  99  98  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 13:28:42